Please assess the completion status of the following clinical trial:

Trial Title: Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* American Society of Anesthesiologists (ASA) Class \>=4~* Creatinine clearance (CLCR) \< 30 mL/min and clinical indication for dialysis~* Hospitalization at Intensive Care Unit (ICU) and scheduled for a (surgical) procedure under general anesthesia requiring neuromuscular relaxation with the use of rocuronium~* Scheduled for a (surgical) procedure in supine position~* Written informed consent (of the legal representative)~Exclusion Criteria:~* Known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant hepatic dysfunction~* Known or suspected to have a (family) history of malignant hyperthermia~* Known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia~* Have already participated in a sugammadex trial~* Have participated in another clinical trial, not preapproved by NV Organon, within 30 days of study entry~* Females who are pregnant\*~* Females who are breast-feeding \* In females pregnancy will be excluded both from medical history and by a human chorionic gonadotropin (hCG) test within 24 hours before surgery except in females who are not of childbearing potential, i.e. at least 2 years menopausal or have undergone tubal ligation or an hysterectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): IV single bolus dose of 4.0 mg/kg sugammadex

Based on this trial design, predict the completion outcome and termination type (if applicable).